
    
      First study of ADX48621 in male and female Parkinson's disease patients with levodopa-induced
      dyskinesia. Four weeks, double-blind, placebo-controlled dose titration from 50 mg once daily
      up to 100 mg three times daily, at the start of week 4. Safety and tolerability assessed by
      adverse events enquiry, heart rate and blood pressure, 12-lead ECG, haematology and
      biochemistry. Efficacy assessments include Abnormal Involuntary Movement Scale (AIMS),
      Unified Parkinson's Disease rating Scale (UPDRS) patient PD symptom diaries, Hospital Anxiety
      Depression Scale (HADS), patient and clinician global impression of change in PD and
      dyskinesia (PGIC and CGIC).
    
  